Trial Outcomes & Findings for Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder (NCT NCT06601907)

NCT ID: NCT06601907

Last Updated: 2026-03-16

Results Overview

The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

286 participants

Primary outcome timeframe

T1 (3 months after randomization)

Results posted on

2026-03-16

Participant Flow

Participant milestones

Participant milestones
Measure
Alivis + Treatment as Usual (TAU)
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Overall Study
STARTED
142
144
Overall Study
COMPLETED
97
96
Overall Study
NOT COMPLETED
45
48

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Total
n=193 Participants
Total of all reporting groups
Age, Continuous
30.70 Years
STANDARD_DEVIATION 8.37 • n=10 Participants
31.77 Years
STANDARD_DEVIATION 8.34 • n=50 Participants
31.23 Years
STANDARD_DEVIATION 8.35 • n=108 Participants
Sex: Female, Male
Female
89 Participants
n=10 Participants
90 Participants
n=50 Participants
179 Participants
n=108 Participants
Sex: Female, Male
Male
8 Participants
n=10 Participants
6 Participants
n=50 Participants
14 Participants
n=108 Participants
Race/Ethnicity, Customized
White
94 Participants
n=10 Participants
89 Participants
n=50 Participants
183 Participants
n=108 Participants
Race/Ethnicity, Customized
Other
3 Participants
n=10 Participants
7 Participants
n=50 Participants
10 Participants
n=108 Participants
BSL-23
2.32 Score
STANDARD_DEVIATION 0.66 • n=10 Participants
2.45 Score
STANDARD_DEVIATION 0.61 • n=50 Participants
2.38 Score
STANDARD_DEVIATION 0.64 • n=108 Participants

PRIMARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Borderline Symptoms List 23 (BSL-23)
1.95 Score
Standard Deviation 0.78
2.00 Score
Standard Deviation 0.80

SECONDARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

The PHQ-9 is the 9-item depression module from the full PHQ with comparable sensitivity and specificity, and includes the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Rating is done on a 4-point Likert scale ranging 0 = "not at all" to 3 = "nearly every day". As a severity measure, scores range from 0 to 27 and represent: mild (0-4), moderate (5-9), moderately severe (10-14), and severe depression (≥15). According to several studies, the German version can be considered reliable regarding psychometric standards. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate fewer depressive symptoms and a better outcome.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Patient Health Questionnaire 9 (PHQ-9)
15.3 Score
Standard Deviation 4.7
15.8 Score
Standard Deviation 5.2

SECONDARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

This self-administered patient questionnaire is used as a screening tool and severity measure for generalized anxiety disorder (GAD). Studies report good reliability, as well as criterion, construct, factorial, and procedural validity. The GAD-7 is scored on a Likert scale ranging from 0 = "not at all" via 1 = "several days" and 2 = "more than half the days" to 3 = "nearly every day", yielding a sum score ranging from 0-21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher total scores indicate greater anxiety symptom severity and thus a worse outcome, whereas lower scores indicate fewer anxiety symptoms and a better outcome.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Generalized Anxiety Disorder Assessment 7 (GAD-7)
12.3 Score
Standard Deviation 4.2
12.2 Score
Standard Deviation 4.1

SECONDARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

Costs caused due to BPD will be assessed with a self-compiled instrument assessing inpatient and outpatient treatment, support from friends, family and professional services, contacts with members of the judicial authorities and public security, medication, sick leave, and physician/therapist visits during work time. Higher values indicate greater resource utilization and higher costs and thus a worse economic outcome, whereas lower values indicate lower resource use and a better economic outcome.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Costs Caused Due to the Patients BPD
2354.8 €
Standard Deviation 5619.7
3290.9 €
Standard Deviation 7468.0

SECONDARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

The WSAS is a 5-item self-report scale to measure social functioning in regard to physical, mental and social health as well as age group referenced competence for performance. The PROM has good psychometric properties with good criterion validity, good sensitivity and strong internal consistency (α = 0.89). Individual items address work, home management, social leisure, private leisure and relationships. Each item is rated on a 9-point Likert scale from 0 = "not at all impaired" to 8 = "very severely impaired". The total score ranges from 0 to 40. Higher total scores indicate greater functional impairment and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Work and Social Adjustment Scale (WSAS)
22.0 Score
Standard Deviation 8.0
22.1 Score
Standard Deviation 7.9

SECONDARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

The PAM-13 assesses patients' active participation in their medical care using 13 items. Items are answered on a Likert scale ranging from 1 = "strongly disagree" to 4 = "strongly agree," yielding a raw total score between 13 and 52. The German version of the PAM-13 (PAM-13-G) is validated and demonstrates good psychometric properties, including good internal consistency (Cronbach's α = 0.84). In this study, raw scores were converted into the standardized 0-100 patient activation score using a min-max transformation, with higher scores indicating greater patient activation and thus a better outcome.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Patient Activation Measure (PAM-13)
65.9 Score
Standard Deviation 13.0
65.7 Score
Standard Deviation 11.9

SECONDARY outcome

Timeframe: T1 (3 months after randomization)

Population: Subset used for interim futility analysis. N is lower than total enrollment due to data cut-off.

The AQoL-8D is a health-related quality-of-life questionnaire consisting of 35 items forming eight health dimensions: independent living, happiness, mental health, coping, relationships, self worth, pain, senses. Validation of the AQoL-8D assessing health-related quality of life showed good psychometric properties in a German patient sample, including excellent reliability (Cronbach's α = 0.96) and construct validity (strong correlation with the SF-36, r = .81). The AQoL-8D score ranges from 0-100; higher scores indicating higher quality of life.

Outcome measures

Outcome measures
Measure
Alivis + Treatment as Usual (TAU)
n=97 Participants
Participants in the intervention group will receive access to alivis in addition to treatment as usual (TAU) for 12 months.
Treatment as Usual (TAU)
n=96 Participants
Participants in the control group will receive access to treatment as usual (TAU) only. They will receive access to alivis after their last study visit (T3; 12 months after randomization).
Assessment of Quality of Life 8 Dimensions (AQoL-8D)
49.9 Score
Standard Deviation 10.6
50.0 Score
Standard Deviation 11.1

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

The AQoL-8D is a health-related quality-of-life questionnaire consisting of 35 items forming eight health dimensions: independent living, happiness, mental health, coping, relationships, self worth, pain, senses. Validation of the AQoL-8D assessing health-related quality of life showed good psychometric properties in a German patient sample, including excellent reliability (Cronbach's α = 0.96) and construct validity (strong correlation with the SF-36, r = .81). The AQoL-8D score ranges from 0-100; higher scores indicating higher quality of life.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

The PAM-13 assesses patients' active participation in their medical care using 13 items. Items are answered on a Likert scale ranging from 1 = "strongly disagree" to 4 = "strongly agree," yielding a raw total score between 13 and 52. The German version of the PAM-13 (PAM-13-G) is validated and demonstrates good psychometric properties, including good internal consistency (Cronbach's α = 0.84). In this study, raw scores were converted into the standardized 0-100 patient activation score using a min-max transformation, with higher scores indicating greater patient activation and thus a better outcome.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

The WSAS is a 5-item self-report scale to measure social functioning in regard to physical, mental and social health as well as age group referenced competence for performance. The PROM has good psychometric properties with good criterion validity, good sensitivity and strong internal consistency (α = 0.89). Individual items address work, home management, social leisure, private leisure and relationships. Each item is rated on a 9-point Likert scale from 0 = "not at all impaired" to 8 = "very severely impaired". The total score ranges from 0 to 40. Higher total scores indicate greater functional impairment and thus a worse outcome, whereas lower scores indicate less disability and a better outcome.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

Costs caused due to BPD will be assessed with a self-compiled instrument assessing inpatient and outpatient treatment, support from friends, family and professional services, contacts with members of the judicial authorities and public security, medication, sick leave, and physician/therapist visits during work time. Higher values indicate greater resource utilization and higher costs and thus a worse economic outcome, whereas lower values indicate lower resource use and a better economic outcome.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

This self-administered patient questionnaire is used as a screening tool and severity measure for generalized anxiety disorder (GAD). Studies report good reliability, as well as criterion, construct, factorial, and procedural validity. The GAD-7 is scored on a Likert scale ranging from 0 = "not at all" via 1 = "several days" and 2 = "more than half the days" to 3 = "nearly every day", yielding a sum score ranging from 0-21. Scores of 5, 10, and 15 are taken as the cut-off points for mild, moderate and severe anxiety, respectively. Higher total scores indicate greater anxiety symptom severity and thus a worse outcome, whereas lower scores indicate fewer anxiety symptoms and a better outcome.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

The PHQ-9 is the 9-item depression module from the full PHQ with comparable sensitivity and specificity, and includes the 9 criteria upon which the diagnosis of DSM-IV depressive disorders is based. Rating is done on a 4-point Likert scale ranging 0 = "not at all" to 3 = "nearly every day". As a severity measure, scores range from 0 to 27 and represent: mild (0-4), moderate (5-9), moderately severe (10-14), and severe depression (≥15). According to several studies, the German version can be considered reliable regarding psychometric standards. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate fewer depressive symptoms and a better outcome.

Outcome measures

Outcome data not reported

OTHER_PRE_SPECIFIED outcome

Timeframe: T2 (6 months after randomization); T3 (12 months after randomization)

The BSL-23 is a 23-item PROM with good psychometric properties that was validated and tested for reliability in a representative German sample (test-retest reliability r = .82, p \< 0.0001; α = 0.94-0.97; high correlation of total score with general psychological burden and depression) to assess the typical symptomatology and severity of BPD. It refers to the last week and has a range from 0 = "not at all" to 4 = "very strong". Its single factor structure was optimized to reflect levels and changes in severity of BPD-symptomatology based on a mean score. Higher mean scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate fewer BPD-related symptoms and a better outcome.

Outcome measures

Outcome data not reported

Adverse Events

Alivis + Treatment as Usual (TAU)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Treatment as Usual (TAU)

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Dr. Gitta Jacob

Gaia AG

Phone: +49 40 3510520

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place